217 related articles for article (PubMed ID: 32468652)
41. Residual pure intralymphatic carcinoma component only (lymphovascular tumor emboli without invasive carcinoma) after neoadjuvant chemotherapy is associated with poor outcome: Not pathologic complete response.
Lee H; Jang Y; Cho YA; Cho EY
Hum Pathol; 2024 Mar; 145():1-8. PubMed ID: 38311186
[TBL] [Abstract][Full Text] [Related]
42. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
43. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.
Guarneri V; Dieci MV; Barbieri E; Piacentini F; Omarini C; Ficarra G; Bettelli S; Conte PF
Ann Oncol; 2013 Dec; 24(12):2990-4. PubMed ID: 24013581
[TBL] [Abstract][Full Text] [Related]
44. Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial.
Thomas JSJ; Provenzano E; Hiller L; Dunn J; Blenkinsop C; Grybowicz L; Vallier AL; Gounaris I; Abraham J; Hughes-Davies L; McAdam K; Chan S; Ahmad R; Hickish T; Houston S; Rea D; Caldas C; Bartlett JM; Cameron DA; Hayward RL; Earl HM
Mod Pathol; 2017 Aug; 30(8):1069-1077. PubMed ID: 28548129
[TBL] [Abstract][Full Text] [Related]
45. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
46. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.
Sheri A; Smith IE; Johnston SR; A'Hern R; Nerurkar A; Jones RL; Hills M; Detre S; Pinder SE; Symmans WF; Dowsett M
Ann Oncol; 2015 Jan; 26(1):75-80. PubMed ID: 25361988
[TBL] [Abstract][Full Text] [Related]
47. Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer.
Kwong MS; Chung GG; Horvath LJ; Ward BA; Hsu AD; Carter D; Tavassoli F; Haffty B; Burtness BA
Cancer J; 2006; 12(3):212-21. PubMed ID: 16803680
[TBL] [Abstract][Full Text] [Related]
48. Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement.
Guerini-Rocco E; Botti G; Foschini MP; Marchiò C; Mastropasqua MG; Perrone G; Roz E; Santinelli A; Sassi I; Galimberti V; Gianni L; Viale G
Tumori; 2022 Jun; 108(3):196-203. PubMed ID: 34918596
[TBL] [Abstract][Full Text] [Related]
49. Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?
Schaefgen B; Mati M; Sinn HP; Golatta M; Stieber A; Rauch G; Hennigs A; Richter H; Domschke C; Schuetz F; Sohn C; Schneeweiss A; Heil J
Ann Surg Oncol; 2016 Mar; 23(3):789-95. PubMed ID: 26467456
[TBL] [Abstract][Full Text] [Related]
50. Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer.
Chen VE; Gillespie EF; Zakeri K; Murphy JD; Yashar CM; Lu S; Einck JP
Adv Radiat Oncol; 2017; 2(2):105-109. PubMed ID: 28740920
[TBL] [Abstract][Full Text] [Related]
51. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
Spring L; Greenup R; Niemierko A; Schapira L; Haddad S; Jimenez R; Coopey S; Taghian A; Hughes KS; Isakoff SJ; Ellisen LW; Smith BL; Specht M; Moy B; Bardia A
J Natl Compr Canc Netw; 2017 Oct; 15(10):1216-1223. PubMed ID: 28982747
[No Abstract] [Full Text] [Related]
52. Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
Yardley DA; Peacock N; Daniel B; Anz B; Molthrop DC; Shroff SK; Young R; Jankov A; Vander Woude A; Shastry M; Pasek J; DeBusk LM; Hainsworth JD
Breast Cancer Res Treat; 2020 Apr; 180(3):647-655. PubMed ID: 32060783
[TBL] [Abstract][Full Text] [Related]
53. Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision.
Govindarajan A; Reidy D; Weiser MR; Paty PB; Temple LK; Guillem JG; Saltz LB; Wong WD; Nash GM
Ann Surg Oncol; 2011 Dec; 18(13):3666-72. PubMed ID: 21590450
[TBL] [Abstract][Full Text] [Related]
54. Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico.
Villarreal-Garza C; Soto-Perez-de-Celis E; Sifuentes E; Ruano S; Baez-Revueltas B; Lara-Medina F; Arce-Salinas C; Alvarado-Miranda A; Chavarri-Guerra Y; Caro-Sanchez C; Castañeda-Soto N; Bargallo-Rocha E; Mohar A
Breast; 2015 Jun; 24(3):218-23. PubMed ID: 25698148
[TBL] [Abstract][Full Text] [Related]
55. Outcomes of Breast Cancer Patients with High Volume of Residual Disease Following Neoadjuvant Chemotherapy.
Zhang YH; Montagna G; Flynn J; Gillespie EF; Mamtani A; Zhang Z; Braunstein LZ; Powell SN; Morrow M; Barrio A; Khan AJ
Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):622-628. PubMed ID: 36155213
[TBL] [Abstract][Full Text] [Related]
56. The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer.
Leon-Ferre RA; Hieken TJ; Boughey JC
Ann Surg Oncol; 2021 Apr; 28(4):2111-2119. PubMed ID: 33486641
[TBL] [Abstract][Full Text] [Related]
57. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
[TBL] [Abstract][Full Text] [Related]
58. Residual lymph node disease after neoadjuvant chemotherapy predicts an increased risk of lymphedema in node-positive breast cancer patients.
Specht MC; Miller CL; Skolny MN; Jammallo LS; O'Toole J; Horick N; Isakoff SJ; Smith BL; Taghian AG
Ann Surg Oncol; 2013 Sep; 20(9):2835-41. PubMed ID: 23689935
[TBL] [Abstract][Full Text] [Related]
59. Does Residual Cancer Burden Predict Local Recurrence After Neoadjuvant Chemotherapy?
Pestana CV; Livasy CA; Donahue EE; Neelands B; Tan AR; Sarantou T; Hadzikadic-Gusic L; White RL
Ann Surg Oncol; 2022 Nov; 29(12):7716-7724. PubMed ID: 35810226
[TBL] [Abstract][Full Text] [Related]
60. Assessment of residual cancer burden and survival in neoadjuvant chemotherapy of inoperable stage III breast cancer: A ten-year follow-up analysis in Vietnam.
Pham HK; Le TD; Nguyen TP; Le TU; Ta HH; Nguyen VC
Pathol Res Pract; 2024 Feb; 254():155099. PubMed ID: 38244433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
